Alnylam Pharmaceuticals’ (ALNY) Market Perform Rating Reaffirmed at Leerink Swann
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “market perform” rating restated by research analysts at Leerink Swann in a research note issued to investors on Friday. They presently have a $72.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $83.00. Leerink Swann’s price target indicates a potential downside of 2.29% from the stock’s previous close. The analysts noted that the move was a valuation call.
Other equities analysts have also issued reports about the stock. Morgan Stanley reissued an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 16th. Ladenburg Thalmann Financial Services set a $80.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 17th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a research note on Monday, May 15th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 26th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $83.50.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 73.69 on Friday. The firm’s market capitalization is $6.76 billion. The firm has a 50-day moving average of $81.97 and a 200-day moving average of $67.40. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $89.45.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same period in the prior year, the business earned ($1.05) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 82.9% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.18) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals’ (ALNY) Market Perform Rating Reaffirmed at Leerink Swann” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/08/alnylam-pharmaceuticals-inc-alny-given-hold-rating-at-leerink-swann.html.
A number of hedge funds have recently made changes to their positions in ALNY. First Manhattan Co. bought a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $148,000. QS Investors LLC increased its stake in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares in the last quarter. Westpac Banking Corp bought a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at $202,000. Finally, The Manufacturers Life Insurance Company increased its stake in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares in the last quarter. Institutional investors and hedge funds own 94.27% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.